Kineta (KANT) 8-K Proteostasis Therapeutics Announces Broad New Dataset from

Exhibit 99.1

Proteostasis Therapeutics Announces Broad New Dataset from

Proprietary Combination andAdd-On CFTR Modulator Studies in Cystic Fibrosis Patients

Greatest ppFEV₁ Improvement Shown in High Dose Triplet with Mean Absolute Improvement in ppFEV₁ of 8 Percentage Points at 14 Days Compared to Placebo (p<0.05) in Subjects with Two F508del Mutations (F/F) Not Predisposed to Rapid Pulmonary Decline

All Combinations Studied Were Well-Tolerated, Including in Difficult to Treat Patients Predisposed to Rapid Pulmonary Decline

Phase 2 Doses Identified for Proprietary Combination, On Track for Mid 2020 Phase 3 Launch

Company to Host Conference Call and Webcast Today at 8:00 AM ET

BOSTON, Mass. – March 25, 2019 – Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced results from Phase 1 clinical studies of its proprietary cystic fibrosis transmembrane conductance regulator (CFTR) modulators:PTI-801, a third-generation CFTR corrector;PTI-808, a novel CFTR potentiator; andPTI-428, a novel CFTR amplifier. This comprehensive data set includes efficacy and safety data from14-day studies of PTI’s proprietary combination therapy(PTI-808,PTI-801 andPTI-428), as well as separate studies ofPTI-801 over 14 days andPTI-428 over 28 days asadd-on treatments to background tezacaftor/ivacaftor therapy, in CF subjects. Endpoints including safety, changes in sweat chloride (SC) concentration and in percent predicted FEV₁ (ppFEV₁) were assessed and evaluated.

“With no plateau in ppFEV₁ improvement reached over 14 days in our triplet combination study, we look forward to studying what we believe are the optimal doses for our corrector and potentiator through longer duration trials in subjects who are not predisposed to rapid pulmonary decline. These studies are expected to complete byyear-end 2019 with preliminary data readouts thereafter, in anticipation of ourmid-2020 Phase 3 launch timeline,” said Meenu Chhabra, President and Chief Executive Officer of Proteostasis. Ms. Chhabra added, “Recruiting patients to earlier-stage studies in a highly competitive clinical trial environment is challenging. I’m very proud of the PTI team and the continued execution resulting in dosing of more than 240 subjects since 2016.”

“As we continue to advance our understanding of CF and the wide distribution of patients’ responses to available CFTR modulator therapies, it is becoming increasingly important to have access to additional disease modifying treatment options,” said Jennifer Taylor-Cousar, M.D., M.S.C.S., Associate Professor of Medicine and Pediatrics, andCo-Director and CF Therapeutics Development Network Director of the Adult CF Program at National Jewish Health. “Data with dual and triple combinations from PTI fuels hope within the CF treatment community that we might soon be able, if approved, to expand our armamentarium with additional CFTR modulators that will allow us to tailor treatment. We look forward to understanding the full potential of these molecules in longer duration studies.”

Proprietary Combination Results in Detail

For PTI’s proprietary triple combination study, 31 subjects were randomized and treated in two dose cohorts determined as part of a pharmacokinetic-pharmacodynamic(PK-PD) model designed to address the combination rule under established regulatory guidance for dose selection in a Phase 3 study, or received placebo. Both active cohorts included the same dose ofPTI-428 (30mg) and either a low dose ofPTI-801 (200 mg) and a high-dose-tested ofPTI-808 (300mg), or a high-dose-tested ofPTI-801 (600mg) and amid-dose ofPTI-808 (150 mg).PTI-808 or placebo was administered in a7-daylead-in period, which was followed by a14-day triple combination treatment period and a subsequent7-day washout period. PK results were as expected and reconfirmed aonce-a-day dosing profile for a triple combination ofPTI-801,PTI-808 andPTI-428.

The compounds were generally well tolerated and there were no serious adverse events or discontinuations reported during the triple combination treatment period. The majority of adverse events reported were mild to moderate in severity. A broad set of inclusion criteria, endorsed by the CF Foundation as a way to enable recruitment due to limited patient availability, were used in the study, resulting in the enrollment of the highest number of subjects predisposed to rapid pulmonary function decline (n=7) across all of the Company’s proprietary combination studies to date.

In a per protocol analysis (PPA) (n=27, limited to subjects compliant to the protocol), aPTI-801 dose-dependent improvement in ppFEV₁ and SC concentration was observed across cohorts. Further, improvement in ppFEV₁ did not reach a plateau by day 14, unlike the response profile in the Company’s previously reportedmid-dose doublet (300mgPTI-801 and 300mgPTI-808) and in reported results fromnon-PTI triple combinations, a finding that affirms PTI’s plan for longer duration studies.

In the PPA population, a statistically significant (p<0.001) mean absolute increase in ppFEV1 at day 14 of 5 percentage points versus baseline was observed in the 600 mgPTI-801 cohort. This cohort also showed a statistically significant decrease in sweat chloride concentration at day 14 of-19 mM (p<0.00001) compared to baseline and-24 mM (p<0.001) compared to placebo with individual improvements of up to 50 mM. Adjusting for subjects predisposed to rapid pulmonary decline (subjects who would be ineligible for other CFTR modulators combination studies), the 600 mgPTI-801 cohort saw an improvement in ppFEV₁ of +6 (p<0.005) versus baseline, and +8 (p<0.05) versus baseline compared to placebo.

In the Company’s doublet study, enrollment remains ongoing in the cohort of 400 mgPTI-801 and 300 mgPTI-808, with 7 subjects recruited to date. As support for the Company’sPK-PD model, a group unblinding of the sweat chloride endpoint was performed, and demonstrated a mean improvement of-20 mM versus baseline (p<0.0005). Factoring in a broad new dataset that includes all double and triple combination14-day studies, the Company’sPK-PD model shows a strong positive relationship between sweat chloride, ppFEV₁improvements and dose levels. This points to a potential best in class doublet combination backbone of 600 mg ofPTI-801 and 300 mg ofPTI-808, which will be further studied and could be used with or withoutPTI-428.

Phase 2 Trials Planned

Based on the totality of data, the Company will be launching three new Phase 2,28-day studies in CF subjects with at least oneF508del mutation. The studies will employ entry criteria comparable to those used in other CFTR modulator combination studies. They will include a placebo controlled, triple and double combination trial in up to 30 patients exploringPTI-801 (600 mg) andPTI-808 (300 mg) with or withoutPTI-428 over a28-day treatment period. PTI’s CFTR modulators will also be evaluated in a homogeneous population over a longer duration. These studies will provide insight on the magnitude ofPTI-428 contribution to efficacy and include:

• PTI-801/808/42828-day study in CF subjects (F508del homozygotes)

• PTI-801/80828-day study in CF subjects (F508del homozygotes)

• PTI-801/808/42828-day study in CF subjects (F508del heterozygotes)

These studies will position the Company to complete Phase 2 enrollment in 2019 and initiate Phase 3 studies inmid-2020, as previously guided.

Add-On Study Results in Detail

For PTI’s two separateadd-on studies, a total of 56 CF subjects who were on background tezacaftor/ivacaftor were randomized and treated with eitherPTI-801 (400 mg) or placebo for 14 days (n=18), orPTI-428 (10 mg or 30 mg) or placebo for 28 days (n=38).

Similar to the Company’s proprietary combination cohorts, these studies were designed with broad entry criteria, endorsed by the CF Foundation as a way to enable recruitment due to limited patient availability. Review of patient medical history records revealed that they experienced an average decline in ppFEV₁ of 3 points despite initiating tezacaftor/ivacaftor therapy; approximately a third of the population had 3 or more pulmonary exacerbations in the 12 months prior to screening, and almost half had previously discontinued lumacaftor/ivacaftor for reasons that included intolerability and lack of benefit. These factors all suggest a strong recruitment bias towards CFTR modulatornon-responders for these studies.

Subjects receivingPTI-801 experienced an average sweat chloride improvement of-20 mM (p<0.05) compared to baseline, with individual improvements approaching or exceeding-40 mM during the treatment period. These subjects did not, however, demonstrate a statistically significant improvement in ppFEV₁ at the end of 14 days of treatment.

Consistent withPTI-428’s mechanism of action, patients at both the 10 mg and 30 mg doses achieved the targeted increase of CFTR protein expression of approximately 50% (p<0.05) through 28 days compared to baseline. These results were obtained via a proprietary CFTR protein ELISA that analyzes samples from the nasal mucosa of study subjects and is an established biomarker for CFTR amplifiers. Similar to thePTI-801 add on study,PTI-428 subjects did not demonstrate a statistically significant improvement in ppFEV₁ at the end of 28 days of treatment.

Conference Call and Webcast

Proteostasis will hold a conference call and accompanying webcast today, March 25, 2019, at 8:00 AM ET to discuss the data announced today. The conference call can be accessed by dialing (844)534-7315 from the United States or (574)990-3007 from outside the United States and referring to conference ID 5397635. A live webcast and accompanying slide presentation will be available on the Investor Events page in the Investors & Media section of the company’s website, www.proteostasis.com. A replay of the webcast will be available on the company’s website shortly after the conclusion of the conference call.

About Proteostasis Therapeutics, Inc.

Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis and other diseases caused by dysfunctional protein processing. Headquartered in Boston, MA, the Proteostasis Therapeutics team focuses on identifying therapies that restore protein function. For more information, visitwww.proteostasis.com.

Safe Harbor

To the extent that statements in this release are not historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “aim,” “may,” “will,” “expect,” “anticipate,” “estimate,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements made in this release include, without limitation, statements regarding the potential of our proprietary combination therapies for the treatment of CF, the potential benefit to patients of our proprietary combination therapies, expected presentations and expected timing of the initiation of, patient enrollment in, data from, and the completion of, our clinical studies and cohorts for our clinical programs. Forward-looking statements made in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations or strategies will be attained or achieved. Such risks and uncertainties include, without limitation, the possibility final or future results from our drug candidate trials (including, without limitation, longer duration studies) do not achieve positive results or are materially and negatively different from or not indicative of the preliminary results reported by the Company (noting that these results are based on a small number of patients and small data set), uncertainties inherent in the execution and completion of clinical trials (including, without limitation, the possibility that FDA comments delay, change or do not permit trial commencement, or intended label, or the FDA requires us to run cohorts sequentially or conduct additional cohorts or pre-clinical or clinical studies), in the enrollment of CF patients in our clinical trials in a competitive clinical environment, in the timing of availability of trial data, in the results of the clinical trials, in possible adverse events from our trials, in the actions of regulatory agencies, in the endorsement, if any, by therapeutic development arms of CF patient advocacy groups (and the maintenance thereof), and those set forth in our Annual Report on Form 10-K for the year ended December 31, 2018 and our other SEC filings. We assume no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACTS:

Investors:

David Pitts / Claudia Styslinger

Argot Partners

212.600.1902

david@argotpartners.com /claudia@argotpartners.com

Media:

David Rosen

Argot Partners

212.600.1902

david.rosen@argotpartners.com